CLOSTRIDIUM DIFFICILE DIAGNOSTICS MARKET ANALYSIS

Clostridium Difficile Diagnostics Market, by Diagnostic Test (Enzyme Immunoassays, Real-Time Polymerase Chain Reaction (RT-PCR), Nucleic Amplification Tests (NAAT), Stool Test (GDH Antigen Test and Toxin A and B Test), Blood Test, Colonoscopy or Sigmoidoscopy and Others), by End User (Hospitals, Diagnostic Centers, Specialty Clinics and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Nov 2022
Code : CMI5315
Pages :177
Formats :
Excel and PDF
Industry : Biotechnology

Market Challenges And Opportunities

Global Clostridium Difficile Diagnostics Market: Restraint

Low awareness about clostridium difficile infection symptoms and associated effects is expected to restrain the growth of the clostridium difficile diagnostics market over the forecast period.

For instance, according to an article published by Cambridge University, in 2017, titled ‘Prevalence of Clostridium difficile infection and colonization in a tertiary hospital and elderly community of North-Eastern Peninsular Malaysia’, an awareness survey population was conducted amongst University hospital staff (i.e. doctors, non-clinical medical professionals, and paramedics) and students (i.e. undergraduates and postgraduates) who were involved with in-hospital patient care, which comprised of five multiple-choice questions.

Global Clostridium Difficile Diagnostics Market- Drivers

The increasing prevalence of clostridium difficile infection (CDI) is anticipated to boost the demand for its diagnosis, which is expected to drive the global clostridium difficile diagnostics market growth.

Moreover, increasing approval of diagnostics tests/assays by regulatory authorities is expected to drive the market growth over the forecast period.